Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 2.16% is 69% below its 5-year average of 7.08%, near the low end of its 5-year range (0.94%–15.90%).
42.32% below its 12-month average of 3.75%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
2.16%
RETURN ON ASSETS (ROA) AVG TTM
3.75%
RETURN ON ASSETS (ROA) AVG 3Y
6.08%
RETURN ON ASSETS (ROA) AVG 5Y
7.08%
RETURN ON ASSETS (ROA) AVG 10Y
7.27%
RETURN ON ASSETS (ROA) AVG 15Y
6.02%
RETURN ON ASSETS (ROA) AVG 20Y
5.57%
CURRENT VS TTM AVG
-42.32%
CURRENT VS 3Y AVG
-64.49%
CURRENT VS 5Y AVG
-69.48%
CURRENT VS 10Y AVG
-70.28%
CURRENT VS 15Y AVG
-64.13%
CURRENT VS 20Y AVG
-61.19%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-57.98%
vs the sector median at left
Pfizer Inc.
Market Cap
$158.39B
Return on Assets (ROA)
2.16%
TTM Avg
3.75%
3Y Avg
6.08%
5Y Avg
7.08%
Market Cap
$144.25B
Return on Assets (ROA)
4.33%
TTM Avg
4.68%
3Y Avg
5.89%
5Y Avg
6.01%
Market Cap
$182.06B
Return on Assets (ROA)
-6.56%
TTM Avg
7.62%
3Y Avg
7.90%
5Y Avg
6.83%
Market Cap
$134.24B
Return on Assets (ROA)
16.06%
TTM Avg
6.37%
3Y Avg
11.74%
5Y Avg
14.58%
Market Cap
$182.59B
Return on Assets (ROA)
4.97%
TTM Avg
11.99%
3Y Avg
10.28%
5Y Avg
9.45%
Market Cap
$132.14B
Return on Assets (ROA)
10.59%
TTM Avg
-0.92%
3Y Avg
3.28%
5Y Avg
1.99%
Market Cap
$123.70B
Return on Assets (ROA)
15.04%
TTM Avg
13.09%
3Y Avg
12.00%
5Y Avg
11.68%
Market Cap
$122.58B
Return on Assets (ROA)
1.93%
TTM Avg
1.25%
3Y Avg
1.93%
5Y Avg
2.38%
Market Cap
$118.26B
Return on Assets (ROA)
410.52%
TTM Avg
5.13%
3Y Avg
4.62%
5Y Avg
4.65%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $158.39B | 2.16% | 3.75% | 6.08% | 7.08% |
| Danaher Corporation (DHR)vs › | $144.25B | 4.33% | 4.68% | 5.89% | 6.01% |
| Gilead Sciences, Inc. (GILD)vs › | $182.06B | -6.56% | 7.62% | 7.90% | 6.83% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.24B | 16.06% | 6.37% | 11.74% | 14.58% |
| Abbott Laboratories (ABT)vs › | $182.59B | 4.97% | 11.99% | 10.28% | 9.45% |
| Bristol-Myers Squibb Company (BMY)vs › | $132.14B | 10.59% | -0.92% | 3.28% | 1.99% |
| Intuitive Surgical, Inc. (ISRG)vs › | $123.70B | 15.04% | 13.09% | 12.00% | 11.68% |
| CVS Health Corp. (CVS)vs › | $122.58B | 1.93% | 1.25% | 1.93% | 2.38% |
| Medtronic plc (MDT)vs › | $118.26B | 410.52% | 5.13% | 4.62% | 4.65% |
| Novo Nordisk A/S (NVO)vs › | $200.54B | 19.90% | 20.27% | 22.54% | 48.60% |
ROA
2.2%
ROE
5.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.73% |
| 2024-12-31 | 3.76% |
| 2023-12-31 | 0.94% |
| 2022-12-31 | 15.90% |
| 2021-12-31 | 12.20% |
| 2020-12-31 | 5.94% |
| 2019-12-31 | 9.72% |
| 2018-12-31 | 7.00% |
| 2017-12-31 | 12.40% |
| 2016-12-31 | 4.20% |
| 2015-12-31 | 4.16% |
| 2014-12-31 | 5.36% |
| 2013-12-31 | 6.77% |
| 2012-12-31 | 5.27% |
| 2011-12-31 | 4.63% |
| 2010-12-31 | 4.24% |
| 2009-12-31 | 4.05% |
| 2008-12-31 | 7.22% |
| 2007-12-31 | 7.12% |
| 2006-12-31 | 9.60% |
| 2005-12-31 | 6.47% |
| 2004-12-31 | 9.16% |
| 2003-12-31 | 3.35% |
| 2002-12-31 | 19.69% |
| 2001-12-31 | 19.89% |
| 2000-12-31 | 11.12% |
| 1999-12-31 | 15.45% |
| 1998-12-31 | 18.31% |
| 1997-12-31 | 14.43% |
| 1996-12-31 | 13.15% |
